CVS reports on Sovaldi discontinuation rates

Discontinuation rates for HCV drug Sovaldi sofosbuvir from Gilead Sciences Inc. (NASDAQ:GILD) were nearly four times higher in a real-world setting than in clinical trials, according to an Olysio simeprevir from Medivir AB (SSE:MVIR B) and Johnson & Johnson (NYSE:JNJ).

Across all regimens, CVS said treatment-naïve patients were significantly more likely to discontinue therapy than treatment-experienced patients (8.7% vs. 5.3%, p<0.05). ...